New study and promising results from the first clinical trial in patients provide novel insights and new hope for one of the deadliest of cancers. Gastric cancer remains a formidable adversary, ...
Gastric cancer remains a formidable adversary, ranking as the fifth most common cancer and the third-leading cause of cancer-related deaths worldwide, with over 1,000,000 new cases and close to ...
Gastric cancers commonly spread to the peritoneum. Its presence significantly alters patient prognosis and treatment-intent; however, current methods of peritoneal staging are inaccurate. Peritoneal ...
Zejula can now be used as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk after ...
A Q&A with Michael Foote, MD, MSK Gastrointestinal Medical Oncologist and member of the Peritoneal Surface Malignancies Consortium Group The Peritoneal Surface Malignancies Consortium Group (PSM ...
7don MSN
I Was 21 When My Doctors Told Me I Had A Year To Live. What Happened Next Left Them Stunned.
"The prognosis was so poor that the hospital called in grief counsellors to speak with my family and help prepare them." ...
Validity of the Patient-Reported Outcome Measurement Information System (PROMIS) Sexual Interest and Satisfaction Measures in Men Following Radical Prostatectomy Compared with CRSa, CRS-HIPEC improved ...
The European Medicines Agency (EMA) has determined that the medicinal product Elahere (mirvetuximab soravtansine, AbbVie Deutschland), indicated for the treatment of adults with folate receptor alpha ...
CRS-HIPEC stands for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. It’s pronounced “high-peck.” This treatment is for people with cancer that has spread to the lining of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback